Annexin A5 directly interacts with amyloidogenic proteins and reduces their toxicity

Biochemistry

Volumn 48, Issue 44, 2009, Pages 10568-10576

  Bedrood, Sahar ^a   Jayasinghe, Sajith ^b   Sieburth, Derek ^a   Chen, Min ^a   Erbel, Saskia ^c   Butler, Peter C ^d   Langen, Ralf ^a   Ritzel, Robert A ^c,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CALIFORNIA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXINS; CAENORHABDITIS ELEGANS; CELL APOPTOSIS; COEXPRESSED; DISEASE PROGRESSION; ELECTRON PARAMAGNETIC RESONANCE; FIBRIL FORMATION; HUMAN ISLETS; IN-VIVO; INDUCED APOPTOSIS; LEWY BODIES; MISFOLDING; NEURODEGENERATIVE DISEASE; PARKINSON'S DISEASE; PROTEIN MISFOLDING; SYNUCLEIN; SYNUCLEIN PROTEINS; THIOFLAVIN T; TRANSGENIC EXPRESSION; TYPE 2 DIABETES MELLITUS; TYPE-2 DIABETES;

CELL DEATH; GLYCOPROTEINS; OLIGOMERS; PARAMAGNETIC RESONANCE; PARAMAGNETISM; PROTEINS; TOXICITY;

ANTIBIOTICS;

ALPHA SYNUCLEIN; AMYLIN; LIPOCORTIN 5; THIOFLAVINE;

APOPTOSIS; ARTICLE; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; ELECTRON MICROSCOPY; ELECTRON SPIN RESONANCE; HUMAN; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION;

ALPHA-SYNUCLEIN; AMYLOID; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANNEXIN A5; APOPTOSIS; CAENORHABDITIS ELEGANS; DIABETES MELLITUS, TYPE 2; ELECTRON SPIN RESONANCE SPECTROSCOPY; HUMANS; ISLETS OF LANGERHANS; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON; PROTEIN FOLDING;

CAENORHABDITIS ELEGANS; RODENTIA;

EID: 70449459050     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi900608m     Document Type: Article

References (48)

1. Janson, J., Ashley,R.H., Harrison, D., McIntyre, S., and Butler, P. C. (1999) The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48, 491-498. (Pubitemid 29106861)
2. Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T., and Lansbury, P. T., Jr. (2002) Neurodegenerative disease: Amyloid pores from pathogenic mutations. Nature 418, 291.
3. Bates, G. (2003) Huntingtin aggregation and toxicity in Huntington's disease. Lancet 361, 1642-1644.
4. Glabe, C. G., and Kayed, R. (2006) Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology 66, S74-S78.
5. Lansbury, P. T., and Lashuel, H. A. (2006) A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 443, 774-779.
6. Jayasinghe, S. A., and Langen, R. (2007) Membrane interaction of islet amyloid polypeptide. Biochim. Biophys. Acta 6, 6.
7. Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman,C. W., and Glabe, C. G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489.
8. Huang, C. J., Lin, C. Y., Haataja, L., Gurlo, T., Butler, A. E., Rizza, R. A., and Butler, P. C. (2007) High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated β-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes 56, 2016-2027. (Pubitemid 47201819)
9. Anguiano, M., Nowak, R. J., and Lansbury, P. T. Jr. (2002) Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry 41, 11338-11343. (Pubitemid 35050739)
10. Ritzel, R. A., Meier, J. J., Lin, C. Y., Veldhuis, J. D., and Butler, P. C. (2007) Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. Diabetes 56, 65-71.
11. Luibl, V., Isas, J. M., Kayed, R., Glabe, C. G., Langen, R., and Chen, J. (2006) Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J. Clin. Invest. 116, 378-385.
12. Maloy, A. L., Longnecker, D. S., and Greenberg, E. R. (1981) The relation of islet amyloid to the clinical type of diabetes. Hum. Pathol. 12, 917-922.
13. Clark, A., Wells, C. A., Buley, I. D., Cruickshank, J. K., Vanhegan, R. I., Matthews, D. R., Cooper, G. J., Holman, R. R., and Turner, R. C. (1988) Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: Quantitative changes in the pancreas in type 2 diabetes. Diabetes Res. 9, 151-159. (Pubitemid 19105415)
14. Hull, R. L., Westermark, G. T., Westermark, P., and Kahn, S. E. (2004) Islet amyloid: A critical entity in the pathogenesis of type 2 diabetes. J. Clin. Endocrinol. Metab. 89, 3629-3643.
15. Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., and Butler, P. C. (2003) β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52, 102-110. (Pubitemid 36042113)
16. Butler, A. E., Jang, J., Gurlo, T., Carty, M. D., Soeller, W. C., and Butler, P. C. (2004) Diabetes due to a progressive defect in β-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): A new model for type 2 diabetes. Diabetes 53, 1509-1516. (Pubitemid 38697663)
17. Lorenzo, A., Razzaboni, B., Weir, G. C., and Yankner, B. A. (1994) Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 368, 756-760. (Pubitemid 24153418)
18. Zhang, S., Liu, J., Saafi, E. L., and Cooper, G. J. (1999) Induction of apoptosis by human amylin in RINm5F islet β-cells is associated with enhanced expression of p53 and p21WAF1/CIP1. FEBS Lett. 455, 315-320.
19. Saafi, E. L., Konarkowska, B., Zhang, S., Kistler, J., and Cooper, G. J. (2001) Ultrastructural evidence that apoptosis is the mechanism by which human amylin evokes death in RINm5F pancreatic islet β-cells. Cell Biol. Int. 25, 339-350.
20. O'Brien, T. D., Butler, P. C., Kreutter, D. K., Kane, L. A., and Eberhardt, N. L. (1995) Human islet amyloid polypeptide expression in COS-1 cells. A model of intracellular amyloidogenesis. Am. J. Pathol. 147, 609-616.
21. Ritzel, R. A., and Butler, P. C. (2003) Replication increases β-cell vulnerability to human islet amyloid polypeptide-induced apoptosis. Diabetes 52, 1701-1708.
22. Verchere, C. B., D'Alessio, D. A., Palmiter, R. D., Weir, G. C., Bonner-Weir, S., Baskin, D. G., and Kahn, S. E. (1996) Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic β cell expression of human islet amyloid polypeptide. Proc. Natl. Acad. Sci. U.S.A. 93, 3492-3496.
23. Janson, J., Soeller, W. C., Roche, P. C., Nelson, R. T., Torchia, A. J., Kreutter, D. K., and Butler, P. C. (1996) Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc. Natl. Acad. Sci. U.S.A. 93, 7283-7288.
24. Iwai, A. (2000) Properties of NACP/R-synuclein and its role in Alzheimer's disease. Biochim. Biophys. Acta 1502, 95-109.
25. Kahle, P. J., Neumann, M., Ozmen, L., Muller, V., Jacobsen, H., Schindzielorz, A., Okochi, M., Leimer, U., Putten, H., Probst, A., Kremmer, E., Kretzschmar, H. A., and Haass, C. (2000) Subcellular localization of wild-type and Parkinson's disease-associated mutant α-synuclein in human and transgenic mouse brain. J. Neurosci. 20, 6365-6373. (Pubitemid 30834252)
26. Mirzabekov, T. A., Lin, M. C., and Kagan, B. L. (1996) Pore formation by the cytotoxic islet amyloid peptide amylin. J. Biol. Chem. 271, 1988-1992.
27. Rescher, U., and Gerke, V. (2004) Annexins: Unique membrane binding proteins with diverse functions. J. Cell Sci. 117, 2631-2639. (Pubitemid 38997247)
28. Reutelingsperger, C. P. (2001) Annexins: Key regulators of haemostasis, thrombosis, and apoptosis. Thromb. Haemostasis 86, 413-419. (Pubitemid 32663970)
29. Flaherty, M. J., West, S., Heimark, R. L., Fujikawa, K., and Tait, J. F. (1990) Placental anticoagulant protein-I: Measurement in extracellular fluids and cells of the hemostatic system. J. Lab. Clin. Med. 115, 174-181.
30. Romisch, J., Schuler, E., Bastian, B., Burger, T., Dunkel, F. G., Schwinn, A., Hartmann, A. A., and Paques, E. P. (1992) Annexins I to VI: Quantitative determination in different human cell types and in plasma after myocardial infarction. Blood Coagulation Fibrinolysis 3, 11-17.
31. Huber, R., Romisch, J., and Paques, E. P. (1990) The crystal and molecular structure of human annexin V, an anticoagulant protein that binds to calcium and membranes. EMBO J. 9, 3867-3874. (Pubitemid 20379975)
32. Lee, G., Pollard, H. B., and Arispe, N. (2002) Annexin 5 and apolipoprotein E2 protect against Alzheimer's amyloid-β-peptide cytotoxicity by competitive inhibition at a common phosphatidylserine interaction site. Peptides 23, 1249-1263. (Pubitemid 34786704)
33. Crabb, J. W., Miyagi, M., Gu, X., Shadrach, K., West, K. A., Sakaguchi, H., Kamei, M., Hasan, A., Yan, L., Rayborn, M. E., Salomon, R. G., and Hollyfield, J. G. (2002) Drusen proteome analysis: An approach to the etiology of age-related macular degeneration. Proc. Natl. Acad. Sci. U.S.A. 99, 14682-14687.
34. Schlaepfer, D. D., Jones, J., and Haigler, H. T. (1992) Inhibition of protein kinase C by annexin V. Biochemistry 31, 1886-1891.
35. Isas, J. M., Cartailler, J. P., Sokolov, Y., Patel, D. R., Langen, R., Luecke, H., Hall, J. E., and Haigler, H. T. (2000) Annexins V and XII insert into bilayers at mildly acidic pH and form ion channels. Biochemistry 39, 3015-3022. (Pubitemid 30159407)
36. Jayasinghe, S. A., and Langen, R. (2004) Identifying structural features of fibrillar islet amyloid polypeptide using site-directed spin labeling. J. Biol. Chem. 279, 48420-48425.
37. Chen, M., Margittai, M., Chen, J., and Langen, R. (2007) Investigation of R-synuclein fibril structure by site-directed spin labeling. J. Biol. Chem. 282, 24970-24979.
38. Der-Sarkissian, A., Jao, C. C., Chen, J., and Langen, R. (2003) Structural organization of R-synuclein fibrils studied by site-directed spin labeling. J. Biol. Chem. 278, 37530-37535.
39. Padrick, S. B., and Miranker, A. D. (2002) Islet amyloid: Phase partitioning and secondary nucleation are central to the mechanism of fibrillogenesis. Biochemistry 41, 4694-4703.
40. Torok, M., Milton, S., Kayed, R., Wu, P., McIntire, T., Glabe, C. G., and Langen, R. (2002) Structural and dynamic features of Alzheimer's Aβ peptide in amyloid fibrils studied by site-directed spin labeling. J. Biol. Chem. 277, 40810-40815.
41. Margittai, M., and Langen, R. (2004) Template-assisted filament growth by parallel stacking of tau. Proc. Natl. Acad. Sci. U.S.A. 101, 10278-10283.
42. Margittai, M., and Langen, R. (2008) Fibrils with parallel in-register structure constitute a major class of amyloid fibrils: Molecular insights from electron paramagnetic resonance spectroscopy. Q. Rev. Biophys. 41, 265-297.
43. Hamamichi, S., Rivas, R. N., Knight, A. L., Cao, S., Caldwell, K. A., and Caldwell, G. A. (2008) Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model. Proc. Natl. Acad. Sci. U.S.A. 105, 728-733.
44. van Ham, T. J., Thijssen, K. L., Breitling, R., Hofstra, R. M., Plasterk, R. H., and Nollen, E. A. (2008) C. elegans model identifies genetic modifiers of R-synuclein inclusion formation during aging. PLoS Genet. 4, e1000027.
45. Giambanco, I., Sorci, G., Antonioli, S., Rambotti, M. G., Spreca, A., Bocchini, V., and Donato, R. (1993) Immunocytochemical analyses of annexin V (CaBP33) in a human-derived glioma cell line. Expression of annexin V depends on cellular growth state. FEBS Lett. 323, 45-50.
46. Butler, A. E., Janson, J., Soeller, W. C., and Butler, P. C. (2003) Increased β-cell apoptosis prevents adaptive increase in β-cell mass in mouse model of type 2 diabetes: Evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 52, 2304-2314. (Pubitemid 37059501)
47. O'Brien, T. D., Butler, A. E., Roche, P. C., Johnson, K. H., and Butler, P. C. (1994) Islet amyloid polypeptide in human insulinomas. Evidence for intracellular amyloidogenesis. Diabetes 43, 329-336.
48. Lin, C. Y., Gurlo, T., Kayed, R., Butler, A. E., Haataja, L., Glabe, C. G., and Butler, P. C. (2007) Toxic human islet amyloid polypeptide (h-IAPP) oligomers are intracellular, and vaccination to induce anti-toxic oligomer antibodies does not prevent h-IAPP-induced β-cell apoptosis in h-IAPP transgenic mice. Diabetes 56, 1324-1332. (Pubitemid 46715613)